A randomized, open-label, phase II study of afatinib versus cetuximab in patients (pts) with recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Analysis of stage 2 (S2) following crossover

被引：0
|
作者：
Cupissol, Didier
Seiwert, Tanguy Y.
Fayette, Jerome
Ehrnrooth, Eva
Blackman, Alice Sarah
Cong, Xiuyu Julie
Cohen, Ezra E. W.
机构：
[1] Ctr Val dAurelle, Montpellier, France
[2] Univ Chicago, Med Ctr, Chicago, IL 60637 USA
[3] Ctr Leon Berard, F-69373 Lyon, France
[4] Boehringer Ingelheim GmbH & Co KG, Copenhagen, Denmark
[5] Boehringer Ingelheim GmbH & Co KG, Ridgefield, CT USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6001
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A RANDOMIZED, OPEN-LABEL, PHASE II STUDY OF AFATINIB VERSUS CETUXIMAB IN RECURRENT/METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC)
    Seiwert, T. Y.
    Fayette, J.
    Cupissol, D.
    DelCampo, J. M.
    Clement, P. M.
    Tourani, J. M.
    Degardin, M.
    Blackman, A. S.
    Cong, J.
    Solca, F.
    Ehrnrooth, E.
    Cohen, E. E. W.
    ANNALS OF ONCOLOGY, 2012, 23 : 35 - 35
  • [2] A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck
    Seiwert, T. Y.
    Fayette, J.
    Cupissol, D.
    del Campo, J. M.
    Clement, P. M.
    Hitt, R.
    Degardin, M.
    Zhang, W.
    Blackman, A.
    Ehrnrooth, E.
    Cohen, E. E. W.
    ANNALS OF ONCOLOGY, 2014, 25 (09) : 1813 - 1820
  • [3] Randomized, phase II study of ficlatuzumab with or without cetuximab in patients (pts) with cetuximab-resistant, recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)
    Bauman, J. E.
    ANNALS OF ONCOLOGY, 2018, 29
  • [4] EAGLE: A phase 3, randomized, open-label study of durvalumab (D) with or without tremelimumab (T) in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC).
    Licitra, Lisa F.
    Haddad, Robert I.
    Even, Caroline
    Tahara, Makoto
    Dvorkin, Mikhail
    Ciuleanu, Tudor-Eliade
    Clement, Paul M.
    Mesia, Ricard
    Kutukova, Svetlana I.
    Zholudeva, Lyubov
    Daste, Amaury
    Caballero, Javier Daroqui
    Keam, Bhumsuk
    Vynnychenko, Ihor
    Lafond, Cedrik
    Shetty, Jagdish
    Morsli, Nassim
    Mann, Helen
    Fayette, Jerome
    Ferris, Robert L.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [5] Phase 2a Study of Cetuximab and Dasatinib in Patients With Cetuximab-Resistant Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)
    Geiger, J. L.
    Egloff, A. M.
    Ohr, J.
    Stabile, L.
    Gooding, W.
    Flaherty, J.
    Gibson, M.
    Grandis, J.
    Bauman, J. E.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2016, 94 (04): : 930 - 930
  • [6] Petosemtamab compared with investigator's choice monotherapy in previously treated patients (pts) with recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC): A randomized, open-label, phase III trial
    Haddad, R.
    Gillison, M.
    Harrington, K. J.
    Kim, S-B.
    Le Tourneau, C.
    Rosenberg, A.
    Ford, J.
    Shen, Y-M.
    Yao, D.
    Zohren, F.
    Machiels, J-P.
    ANNALS OF ONCOLOGY, 2024, 35 : S653 - S654
  • [7] Randomized, phase II study of ficlatuzumab with or without cetuximab in patients with pan-refractory, recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
    Bauman, Julie E.
    Roe, Denise
    Saba, Nabil F.
    Bauman, Jessica Ruth
    Kaczmar, John M.
    Burtness, Barbara
    Muzaffar, Jameel
    Julian, Ricklie Ann
    Wang, Steven
    Bearelly, Shethal
    Baker, Audrey
    Steuer, Conor Ernst
    Bhatia, Aarti K.
    Giri, Anshu
    Caulin, Carlos
    Stabile, Laura P.
    Centuori, Sara
    Chung, Christine H.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [8] A phase I/Ib study of lenvatinib and cetuximab in patients with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
    Dunn, Lara
    Ho, Alan Loh
    Eng, Juliana
    Michel, Loren S.
    Fetten, James Vincent
    Warner, Elizabeth
    Kriplani, Anuja
    Zhi, Wanqing Iris
    Ng, Kenneth K.
    Haque, Sofia
    Pfister, David G.
    Sherman, Eric Jeffrey
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [9] An open-label, non-randomized, multi-arm, phase II trial evaluating pembrolizumab combined with cetuximab in patients (pts) with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): updated results of cohort 1 analysis
    Sacco, A. G.
    Chen, R.
    Ghosh, D.
    Worden, F.
    Wong, D. J.
    Adkins, D.
    Swiecicki, P. L.
    Chai-Ho, W.
    Pittman, E.
    Messer, K.
    Gold, K. A.
    Daniels, G.
    Sutton, B.
    Natsuhara, A.
    Cohen, E.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 106 (05): : 1121 - 1122
  • [10] A randomized phase II study of cetuximab (C) every 2 weeks at either 500 or 750 mg/m2 for patients (Pts) with recurrent or metastatic (R/M) head and neck squamous cell cancer (HNSCC).
    Fury, M. G.
    Sherman, E. J.
    Lisa, D. M.
    Agarwal, N.
    Algazy, K. M.
    Brockstein, B.
    Langer, C. J.
    Lim, D.
    Mehra, R.
    Rajan, S. K.
    Jafri, N.
    Korte, S.
    Lipson, B.
    Yunus, F.
    Tanvetyanon, T.
    Smith-Marrone, S.
    Ng, K. K.
    Xiao, H.
    Haque, S.
    Pfister, D. G.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345